MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Elixir Medical Corporation

Elixir Medical Announces Key Commercial Milestone With LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL)
From Elixir Medical Corporation
Via GlobeNewswire
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
From Elixir Medical Corporation
Via GlobeNewswire
Elixir Medical Announces Launch of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Europe
From Elixir Medical Corporation
Via GlobeNewswire
TCT 2024: Elixir Medical to Present Clinical Outcomes on Two Transformative Platforms Designed to Advance Cardiovascular Disease Treatment and Intervention
From Elixir Medical Corporation
Via Business Wire
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
From Elixir Medical Corporation
Via Business Wire
Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024
From Elixir Medical Corporation
Via Business Wire
Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease
From Elixir Medical Corporation
Via Business Wire
EuroPCR 2024: Elixir Medical’s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES
From Elixir Medical Corporation
Via Business Wire
Elixir Medical To Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023
From Elixir Medical Corporation
Via Business Wire
Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan’s PMDA Agency for Regulatory Approval
From Elixir Medical Corporation
Via Business Wire
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s DynamX Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
From Elixir Medical Corporation
Via Business Wire
Elixir Medical To Announce Late-Breaking Clinical Data at EuroPCR 2023 Session Featuring World’s First Transforming Coronary Artery Implant Designed to Restore Vessel Physiology and Function
From Elixir Medical Corporation
Via Business Wire
Elixir Medical Expands Leadership Team With Addition of Alexey Nepogodiev as Executive Vice President, Global Marketing
From Elixir Medical Corporation
Via Business Wire
DynamX Bioadaptor Restores Rotational Motion and Vessel Stress Reduction in New Study
From Elixir Medical Corporation
Via Business Wire
Elixir Medical Completes Enrollment in BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System
From Elixir Medical Corporation
Via Business Wire
Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System
From Elixir Medical Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story